Respiratory Market Insight 2008

Chapter 2 Introduction
2.1 Respiratory Diseases Overview
2.2 What is Asthma?
2.2.1 Causes of Asthma
2.2.2 Asthma Triggers
2.2.3 Asthma Rates Have Exploded in Recent Years
2.2.4 The Economic Cost of Asthma Has Increased
2.2.5 Asthma: Drug Treatments
2.2.6 Inhaler is Main Delivery Method for Asthma
2.3 Chronic Obstructive Pulmonary Disease (COPD)
2.3.1 Chronic Bronchitis
2.3.2 Emphysema
2.3.3 Symptoms of COPD
2.3.4 Management of COPD
2.3.5 Frequent Exacerbations in Patients with COPD
2.4 Upper Respiratory Infections (URI)
2.4.1 Common Cold
2.4.2 Influenza
2.4.3 Sinusitis
2.4.4 Pharyngitis / Tonsillitis
2.4.5 Allergic Rhinitis
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Combination
2.5.2 Leukotriene Inhibitors
2.5.3 Corticosteroids
2.5.4 Beta-2 (Adrenoreceptor) Agonists
2.5.5 Antihistamines
2.5.6 Monoclonal Antibodies
2.5.7 Summary of Major Products in the Respiratory Market

Chapter 3 The Global Respiratory Disease Drug Market
3.1 The Global Respiratory Disease Drug Market Will Grow During 2008-2013
3.2 GSK Currently Leads the Respiratory Market
3.3 Combination Drugs to Continue Their Domination of the Respiratory Disease Market, 2006 Onwards
3.4 Other Classes of Respiratory Drugs Will Display High Revenues during 2006-2013
3.5 Antihistamines - Declining Revenues due to Heightened Competition
3.6 B2-Stimulants - Will This Class Be Superseded by the Combination Drugs?
3.7 Corticosteroids - Carving a Secure Niche in a Highly Competitive Market
3.8 Leukotriene Inhibitors Will Maintain a Respected Position in the Respiratory Market
3.9 Competition in the Respiratory Disease Drug Market to Become Increasingly Intense

Chapter 4 The World Market for Combination Drugs, 2008-2013
4.1 Combination Drugs - Strong Growth Leads to Continuing Predominance in the Market
4.1.1 Will the Combination Drugs Hold Their Dominance Towards the End of the Forecast Period?
4.2 GSK’s Advair/Seretide Currently Leads the Respiratory Market
4.2.1 Advair/Seretide Benefits From High Prescription Rates in the US Market
4.2.2 Advair/Seretide Benefits from Further Clinical Studies
4.3 Symbicort - High Revenues Followed by Decline
4.3.1 New Formulation and Delivery Method Looks Promising
4.3.2 New Dosing Regime May Offer Symbicort Significant Market Advantages
4.3.3 Is AstraZeneca Pushing Towards a New Model of Asthma Treatment?
4.4 Combivent Will Reach Blockbuster Status

Chapter 5 The World Market for Antihistamines, 2008-2013
5.1 Increased Competition Will Lower Revenues Among the Antihistamines
5.2 Will Pfizer’s Zyrtec Still Dominate the Antihistamine Market After Patent Expiration?
5.2.1 Zyrtec Faces Generic Competition
5.3 Allegra/Telfast Will Decline in Revenue
5.3.1 Allegra/Telfast has Some Positive and Negative Clinical Data
5.4 Clarinex/Aerius Will Show Some Positive Growth but then Gradually Decline

Chapter 6 The World Market for Corticosteroids, 2008-2013
6.1 Corticosteroids Will Retain Their Niche Despite a Marked Decline in Sales
6.2 Pulmicort from AstraZeneca is the Market Leader – But will it Last?
6.2.1 Why Will Pulmicort's Revenue Drop?
6.3 Flovent/Flixotide Will Gradually Decline in Sales
6.4 Nasonex Will Become the Leading Product in this Market
6.4.1 Nasonex Benefits From the Patent Expiry of Other Leading Products in this Class
6.5 Summary - Corticosteroids

Chapter 7 The World Market for Leukotriene Inhibitors, 2008-2013
7.1 Singulair Dominates the Leukotriene Inhibitor Class
7.2 Summary - Leukotriene Inhibitors

Chapter 8 The World Market for Monoclonal Antibodies, 2008-2013
8.1 The Monoclonal Antibodies Will Face Decreased Growth
8.2 MedImmune’s Synagis Leads This Market
8.2.1 Synagis Benefits from Further Clinical Studies
8.3 Xolair Shows Steady Growth – Will it Become the New Market Leader?

Chapter 9 The World Market for B2-Stimulants, 2008-2013
9.1 B2-Stimulants Will Lose Prominence in the Respiratory Market
9.2 Xopenex Will Dominate the B2-Stimulants Class Despite Mixed Growth
9.3 Serevent Loses Revenue Despite Patent Protection
9.4 Recent Study Confirms Increased Risk With Beta-2 Agonist Usage
9.5 Summary - Beta-2 Agonists

Chapter 10 Analysis of Factors That Influence the Respiratory Market
10.1 SWOT Analysis of the Respiratory Market
10.2 An Expanding Patient Population Constitutes the Principal Driver in the Respiratory Market
10.2.1 The Respiratory Disease Market Has High Potential and Opportunities
10.2.2 Growth in this Market Is Driven by Epidemiological Factors
10.2.3 Lifecycle Management Strategies Will Become More Prominent to Protect Soon-to-be Off-patent Drugs
10.2.4 Brand Awareness in the Respiratory Disease Market
10.3 The Principal Restraints in the Respiratory Market
10.3.1 To What Extent is the Respiratory Market Threatened by Generic Substitutes?
10.3.2 Warnings Act as Restraints to Market Growth
10.3.3 Comparative Studies - A Two Edged Sword
10.4 What has Caused a Broadening of the Focus in Respiratory Drug Development?
10.5 Respiratory Disease - A Unique Market Based on Management Rather than Cure
10.6 Increasing Investment in the ‘Cinderella Sector’
10.7 The Future for Respiratory Disease           Research and Development and the Increasing Focus on
COPD
10.8 The Importance of Education in the Future of the Respiratory Disease Market
10.9 Is the Early Treatment of Asthma the Way Ahead?

Chapter 11 Respiratory Pipeline Products
11.1 Summary of All Respiratory Pipeline Products
11.2 The Respiratory Pipeline is Large
11.3 NVA237 and QVA149 for COPD
11.4 New Companies Seek Entrance Into a Potentially Lucrative Market
11.5 The Potential of the Respiratory Market Has Encouraged R&D
11.6 Innovation Rules For Early Stage Pipeline Drugs
11.7 Respiratory Pipeline Shows Short- and Long-Term Potential

Chapter 12 Conclusion
12.1 The Respiratory Market Constitutes a High Revenue Market with Continuing Growth Potential
12.2 Combination Class Will Dominate During the Forecast Period
12.3 Unmet Needs in the Market
12.4 Future Opportunities in the Respiratory Market

List of Tables
Table 1.1 Blockbuster Drugs in the World Respiratory Market
Table 2.1 Summary of the Major Products in the Respiratory Market and Revenues ($m), 2006
Table 3.1 Blockbuster Drugs in the World Respiratory Disease Market, 2006
Table 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
Table 3.3 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Respiratory Drugs by Class, 2006 & 2013
Table 4.1 World Revenues ($m) for Combination Drugs, 2008-2013
Table 4.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Combination Drugs, 2006 & 2013
Table 5.1 World Revenues ($m) for Antihistamines, 2008-2013
Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Antihistamines, 2006 & 2013
Table 6.1, World Revenues ($m) for Corticosteroids, 2008-2013
Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Corticosteroids, 2006 & 2013
Table 7.1 World Revenues ($m) and Growth Rate (%) for Singulair, 2008-2013
Table 8.1 World Revenues ($m) for Monoclonal Antibodies, 2008-2013
Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Monoclonal Antibodies, 2006 & 2013
Table 9.1 World Revenues ($m) for B2-Stimulants, 2008-2013
Table 9.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for B2-Stimulants, 2006 & 2013
Table 10.1 A SWOT Chart for the Respiratory Market, 2008-2013
Table 11.1 Pipeline Drugs for Respiratory Diseases, 2008

List of Figures
Figure 1.1 Market Share (%) for the Respiratory Market by Company, 2006
Figure 3.1 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
Figure 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
Figure 3.3 World Market Share (%) for Respiratory Drugs by Class, 2006
Figure 3.4 World Market Share (%) for Respiratory Drugs by Class, 2013
Figure 4.1 Total World Revenues ($m) for Combination Drugs, 2008-2013
Figure 4.2 World Revenues ($m) for the Combination Drugs by Leading Product, 2008-2013
Figure 4.3 World Market Share (%) for Combination Drugs by Leading Product, 2006
Figure 4.4 World Market Share (%) for Combination Drugs by Leading Product, 2013
Figure 4.5 World Advair/Seretide Revenues ($m), 2008-2013
Figure 4.6 World Symbicort Revenues ($m), 2008-2013
Figure 4.7 World Combivent Revenues ($m), 2008-2013
Figure 5.1 Total World Revenues ($m) for Antihistamines, 2008-2013
Figure 5.2 World Revenues ($m) for the Antihistamines by Leading Product, 2008-2013
Figure 5.3 World Market Share (%) for Antihistamines by Product, 2006
Figure 5.4 World Market Share (%) for Antihistamines by Product, 2013
Figure 5.5 World Zyrtec Revenues ($m), 2008-2013
Figure 5.6 World Allegra/Telfast Revenues ($m), 2008-2013
Figure 5.7 World Clarinex/Aerius Revenues ($m), 2008-2013
Figure 6.1 Total World Revenues ($m) for Corticosteroids, 2008-2013
Figure 6.2 World Revenues ($m) for the Corticosteroids by Leading Product, 2008-2013
Figure 6.3 World Market Share (%) for Corticosteroids, 2006
Figure 6.4 World Market Share (%) for Corticosteroids, 2013
Figure 6.5 World Pulmicort Revenues ($m), 2008-2013
Figure 6.6 Flovent/Flixotide Revenues ($m), 2008-2013
Figure 6.7 World Nasonex Revenues ($m), 2008-2013
Figure 7.1 World Revenues ($m) for Singulair, 2008-2013
Figure 8.1 Total World Revenues ($m) for Monoclonal Antibodies, 2008-2013
Figure 8.2 World Revenues ($m) for the Monoclonal Antibodies by Leading Product, 2008-2013
Figure 8.3 World Market Share (%) for Monoclonal Antibodies, 2006
Figure 8.4 World Market Share (%) for Monoclonal Antibodies, 2013
Figure 8.5 World Synagis Revenues ($m), 2008-2013
Figure 8.6 World Xolair Revenues ($m), 2008-2013
Figure 9.1 Total World Revenues ($m) for B2-Stimulants, 2008-2013
Figure 9.2 World Revenues ($m) for the B2-Stimulants by Leading Product, 2008-2013
Figure 9.3 World Market Share (%) for B2-Stimulants, 2006
Figure 9.4 World Market Share (%) for B2-Stimulants, 2013
Figure 9.5 World Xopenex Revenues ($m), 2008-2013
Figure 9.6 World Serevent Revenues ($m), 2008-2013